|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||85.51 - 86.38|
|52 Week Range||64.18 - 89.09|
|PE Ratio (TTM)||37.37|
|Earnings Date||Oct 24, 2017|
|Forward Dividend & Yield||2.08 (2.42%)|
|1y Target Est||91.05|
Oct.19 -- Ken Langone, chairman at Invemed Associates and co-founder at Home Depot, recounts his experience during the Black Monday market crash in 1987 and the future of financial regulation. He speaks with Bloomberg's Jason Kelly from the Robin Hood Investors Conference on "Bloomberg Markets."
WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is effective, reasonably safe and should be approved by the FDA. The panel voted 16-0 with one abstention in favor of the drug being approved.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
In 1H17, Eli Lilly's (LLY) Cymbalta reported revenues of around $381.2 million, compared with $435.2 million in 1H16.
In 1H17, Eli Lilly’s (LLY) Humalog reported revenues of around $1.39 million, compared with $1.31 million in 1H16.
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
In 1H17, Eli Lilly's (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.
U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA (mRNA) technology. Under terms of the deal, CureVac will receive $50 million up front and Lilly will take an equity stake in CureVac worth about $53 million (45 million euros).
INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tumor neoantigens for a more robust anti-cancer immune response.
U.S. President Donald Trump is leaning toward naming former pharmaceutical industry executive Alex Azar as his pick to lead the Department of Health and Human Services, Politico reported on Tuesday, citing ...
INDIANAPOLIS , Oct. 16, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding common ...
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.
Data presented at 18th World Conference on Lung Cancer INDIANAPOLIS , Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA ® (ramucirumab) ...
In September, the FDA approved Eli Lilly's (LLY) Verzenio-fulvestrant combination therapy for the treatment of women with hormone receptor-positive or HR+.